Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
31/435
Résultats pour
“Viruses”
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
…Co-infection with other hepatitis viruses and low CD4-nadir, but not…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
…prevention of transmission of bloodborne viruses, including HCV. They are intended for…
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
…in hepatitis B and C viruses and alcoholic liver disease, with a…
-
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.
### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…
-
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Hepatitis C virus (HCV) infection is a major cause of chronic liver…
-
Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…
-
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…
-
Retracted: Executive functions in chronic hepatitis C virus infected elderly patients.
-
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. Meta Analysis
### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…
-
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
In therapy with standard interferon and ribavirin, five independent risk factors (RF…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
### Objectives Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in…
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Although most hepatitis C virus (HCV) infections are acquired by injection drug…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
### Background Our aim was to assess the natural history of liver fibrosis…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
### Background & Aims Data on liver fibrosis evolution and its involvement in liver…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
The non-invasive assessment of hepatic fibrosis. Review
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Management of the patient with SVR. Review
In the current era of therapy with direct-acting antiviral (DAAs) drugs…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Biomarkers for liver disease in urea cycle disorders.
### Background Urea cycle disorders (UCDs) are among the most common inborn errors…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.